Moore J P, Stevenson M
Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, New York 10021, USA.
Nat Rev Mol Cell Biol. 2000 Oct;1(1):40-9. doi: 10.1038/35036060.
Despite the success of protease and reverse transcriptase inhibitors, new drugs to suppress HIV-1 replication are still needed. Several other early events in the viral life cycle (stages before the viral genome is inserted into host cell DNA) are susceptible to drugs, including virus attachment to target cells, membrane fusion and post-entry events such as integration, accessory-gene function and assembly of viral particles. Among these, inhibitors of virus-cell fusion and integration are the most promising candidates.
尽管蛋白酶抑制剂和逆转录酶抑制剂取得了成功,但仍需要新的药物来抑制HIV-1复制。病毒生命周期中的其他几个早期事件(病毒基因组插入宿主细胞DNA之前的阶段)也易受药物影响,包括病毒与靶细胞的附着、膜融合以及进入后事件,如整合、辅助基因功能和病毒颗粒的组装。其中,病毒-细胞融合和整合抑制剂是最有前景的候选药物。